Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06958211 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 8, 2026 (before its estimated October 9, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status changed: Recruiting → Active, Not Recruiting Enrollment target: estimated 550 to confirmed 573 · Site details revised at 107 of 107 sitesv29 Show 2 more changesShow less
    • Enrollment target: estimated 550 to confirmed 573
    • Site details revised at 107 of 107 sites
  2. Trial sites reduced: 110 → 107 locationsv28
  3. Enrollment target: 450 to 550 Secondary endpoints: 34 to 35v27 Show 1 more changeShow less
    • Secondary endpoints: 34 to 35

    See this version in full on ClinicalTrials.gov ↗

  4. Study sites: 111 to 110v26
  5. Site details revised at 3 of 111 sitesv25
Show 23 earlier versionsHide 23 earlier versions
  1. Site details revised at 4 of 111 sitesv24
  2. Site details revised at 4 of 111 sitesv23
  3. Site details revised at 7 of 111 sitesv22
  4. Site details revised at 1 of 111 sitesv21
  5. Site details revised at 7 of 111 sitesv20
  6. Study sites revised (111)v19 See this version in full on ClinicalTrials.gov ↗
  7. Site details revised at 1 of 111 sitesv18
  8. Site details revised at 11 of 111 sitesv17
  9. Site details revised at 4 of 111 sitesv16
  10. Site details revised at 6 of 111 sitesv15
  11. Site details revised at 8 of 111 sitesv14
  12. Site details revised at 7 of 111 sitesv13
  13. Site details revised at 2 of 111 sitesv12
  14. Study sites: 112 to 111v11
  15. Study sites: 113 to 112v10
  16. Site details revised at 2 of 113 sitesv9
  17. Site details revised at 10 of 113 sitesv8
  18. Site details revised at 3 of 113 sitesv7
  19. Study sites: 112 to 113 Start date changed from estimate of Jun 11, 2025 to Jun 12, 2025v6 Show 1 more changeShow less
    • Start date changed from estimate of Jun 11, 2025 to Jun 12, 2025
  20. Site details revised at 3 of 112 sitesv5
  21. Study sites: 106 to 112v4
  22. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 106 · Secondary endpoints: details revised at 1 of 34 entriesv3 Show 2 more changesShow less
    • Study sites: 0 to 106
    • Secondary endpoints: details revised at 1 of 34 entries
  23. Study title expanded, about 1 wordv2 See this version in full on ClinicalTrials.gov ↗
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
Trial Details
NCT Number NCT06958211
Lead Sponsor Incyte Corporation
Conditions Hidradenitis Suppurativa
Enrollment 573 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov